Clinical Trial Update: Uncommon EGFR AZD9291 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for an EGFR-directed therapy (AZD9291) in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN